Document Detail

Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
MedLine Citation:
PMID:  11805499     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate topical interferon alpha-2b (IFNalpha2b) as a lone therapy in the treatment of primary conjunctival and corneal intraepithelial neoplasia (CIN). METHODS: Noncomparative, prospective, interventional case series. Seven patients from three institutions, treated between February and October 1999, with presumed primary CIN lesions (clinically diagnosed by corneal specialists) were given topical IFNalpha2b drops (1 million units/mL) four to six times daily. Follow-up was performed biweekly until there was complete clinical resolution of the presumed CIN lesions. Patients were to continue topical IFNalpha2b drops for 1 month after clinical resolution. Patient charts and clinical photographs were reviewed, and data were analyzed. RESULTS: All seven eyes had complete resolution of the presumed CIN lesions after an average of 77.0 +/- 59.2 days (range, 28-188 days). Average posttreatment follow up was 12.4 +/- 2.5 months (range, 9-16 months). No patients were lost to follow-up. No recurrences have yet been seen. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in four (57.1%) eyes. In all cases, there was total resolution of conjunctival hyperemia and follicular changes within 1 month after cessation of the medication, without additional treatment. CONCLUSIONS: Topical IFNalpha2b alone may be an effective treatment of primary CIN. It appears to be a safe alternative to radiation, intralesional IFNalpha2b injection, and surgical excision with cryotherapy. Larger population studies with longer follow-up are recommended to better assess the risk of recurrence and other possible adverse effects.
Barry A Schechter; Amilia Schrier; Robert S Nagler; Edward F Smith; Gabriel E Velasquez
Related Documents :
9797659 - Do patients with age related maculopathy and cataract benefit from cataract surgery?
11687359 - Patient satisfaction after uneventful cataract surgery with implantation of a silicone ...
20463799 - The effect of pterygium surgery on contrast sensitivity and corneal topographic changes.
18812129 - Accuracy of preoperative biometry in vitrectomy combined with cataract surgery for pati...
17964399 - Ketorolac tromethamine ls 0.4% versus nepafenac 0.1% in patients having cataract surger...
12231309 - Transient corneal edema after phacoemulsification: comparison of 3 viscoelastic regimens.
21063919 - Nonarteritic anterior ischemic optic neuropathy.
25412669 - Electroacupuncture for the prevention of postoperative gastrointestinal dysfunction in ...
17469029 - Impact of the degree of hydronephrosis on the efficacy of in situ extracorporeal shock-...
Publication Detail:
Type:  Case Reports; Clinical Trial; Journal Article    
Journal Detail:
Title:  Cornea     Volume:  21     ISSN:  0277-3740     ISO Abbreviation:  Cornea     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-01-28     Completed Date:  2002-05-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  6-11     Citation Subset:  IM    
Rand Eye Institute, Pompano Beach, Florida 33064, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Aged, 80 and over
Antineoplastic Agents / administration & dosage,  therapeutic use*
Carcinoma in Situ / drug therapy*
Conjunctival Neoplasms / drug therapy*
Corneal Diseases / drug therapy*
Eye Neoplasms / drug therapy*
Interferon Alfa-2b / administration & dosage,  therapeutic use*
Middle Aged
Ophthalmic Solutions
Remission Induction
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ophthalmic Solutions; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacologic treatments for dry eye: a worthwhile investment?
Next Document:  The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal...